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Tumor cells have high-energetic and anabolic needs
and are known to adapt their metabolism to be able
to survive and keep proliferating under conditions
of nutrient stress. We show that PKCz deficiency
promotes the plasticity necessary for cancer cells
to reprogram their metabolism to utilize glutamine
through the serine biosynthetic pathway in the
absence of glucose. PKCz represses the expression
of two key enzymes of the pathway, PHGDH and
PSAT1, and phosphorylates PHGDH at key residues
to inhibit its enzymatic activity. Interestingly, the loss
of PKCz in mice results in enhanced intestinal tumor-
igenesis and increased levels of these two metabolic
enzymes, whereas patients with low levels of PKCz
have a poor prognosis. Furthermore, PKCz and
caspase-3 activities are correlated with PHGDH
levels in human intestinal tumors. Taken together,
this demonstrates that PKCz is a critical metabolic
tumor suppressor in mouse and human cancer.INTRODUCTION
The phenomenon widely known as theWarburg effect describes
the ability of tumor cells to rely on aerobic glycolysis to main-
tain cell growth and proliferation. This provides a rapid way to
produce the energy and metabolites required for the high rate
of anabolism that drives the dramatically increased proliferation
of cancer cells (Vander Heiden et al., 2009). However, although
cells undergoing the Warburg effect are empowered to rapidly
proliferate when glucose is plentiful, a flexible and adaptive
metabolic program would allow them to better respond to
changes in nutrient availability and metabolic stress conditions.
In addition to glucose, tumor cells can metabolize glutamine,
whose transport into the cell is dramatically enhanced during
transformation (DeBerardinis and Cheng, 2010; Fuchs and
Bode, 2006). Glutamine is a very versatile metabolite becauseit can not only provide ATP by oxidation through the Krebs cycle
but also generate nitrogen for nucleotide synthesis, and it is
a precursor of glutathione, helping to control the side effects of
oxidative stress (DeBerardinis and Cheng, 2010).
In theory, therapies aimed at curtailing glucose utilization by
‘‘glucose-addicted’’ cancer cells could be efficacious in treating
tumors with relative specificity. However, this approach will
invariably trigger nutrient stress, which is often observed in
aggressive tumors, even at early stages, and correlates with
poor patient survival (Le et al., 2006; Swinson et al., 2003).
Signaling molecules that prevent this adaptive response to
nutrient stress are predicted to act as tumor suppressors. In
this paper, we have addressed this hypothesis in the context
of the tumor suppressor role and mechanism of action of
PKCz. This is one of the two members of the atypical PKC
family of isoenzymes (aPKCs) whose genetic inactivation in
mice leads to enhanced tumorigenesis in a model of Ras-
induced lung carcinogenesis (Galvez et al., 2009). Here, we
report that PKCz-deficient cells reprogram their metabolism for
the utilization of glutamine instead of glucose through the serine
biosynthetic cascade controlled by 3-phosphoglycerate dehy-
drogenase (PHGDH). This is particularly relevant in light of recent
findings suggesting a critical role for this newly identified meta-
bolic cascade in oncogenesis (Locasale et al., 2011; Possemato
et al., 2011). Therefore, PKCz emerges as a critical regulator of
tumor metabolism.
RESULTS
Control of Nutrient Stress in Cancer Cells by PKCz
Our previous studies suggested that the loss of PKCz in Ras-
transformed cells served to confer resistance to stress due to
nutrient exhaustion (Galvez et al., 2009). However, the conditions
of nutrient scarcity were poorly defined in those studies (Galvez
et al., 2009). Here, we sought to investigate the molecular and
cellular mechanisms accounting for the tumor suppressor ac-
tivity of PKCz as a potential regulator of the cellular response
to metabolic stress. We infected SW480 cells with lentivirus ex-
pressing PKCz RNAi (shPKCz), after which their proliferative
properties were compared to those cells with unaltered levelsCell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc. 599
Figure 1. Control of Metabolic Stress by PKCz
(A) Cell lysates from SW480 control (shNT) or PKCz-deficient (shPKCz) cells cultured under nutrient exhaustion conditions were analyzed by immunoblotting with
PKCz, active caspase-3, and actin antibodies. Results are representative of three experiments.
(B and C) Glucose and glutamine levels in the media of SW480 shNT or shPKCz cells cultured as above. Results are the mean ± SEM (n = 3).
(D) Cell viability of SW480 shNT or shPKCz cells cultured under nutrient exhaustion conditions. Number of cells was determined by trypan blue exclusion assay.
Values are mean ± SEM of triplicates for three different experiments.
(E and F) The net consumption of glucose and production of lactate by SW480 shNT or shPKCz cells was determined at 24 hr by enzymatic assay. Results are the
mean ± SEM (n = 4).
(G) Caspase-3 activity was determined by FACS in SW480 shNT or shPKCz cells cultured under glucose-deprived conditions. Results are themean ±SEM (n = 3).
(H) Cell viability of SW480 shNT, shPKCz, or shPKCz cells reconstituted with either WT or kinase-dead PKCz cultured under glucose-deprived conditions.
Number of cells was determined by trypan blue exclusion assay. Results aremean ±SEM (n = 3). Expression of HA-tagged retroviral constructs was confirmed by
immunoblotting with HA antibody (right).
(I) Cell viability of SW620 cells stably expressing WT or kinase-dead (KD) PKCz cultured under nutrient stress conditions for 5 days. Number of cells was
determined by trypan blue exclusion assay. Results are mean ± SEM (n = 3). Expression of HA-tagged retroviral constructs was confirmed by immunoblotting
with HA antibody (inset).
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S1.of PKCz (infected with a control lentivirus; shNT). The elimination
of endogenous PKCz was >90% efficient as determined by
immunoblot densitometry (Figure 1A, upper). We next cultured
both cell types without subsequent media changes, which led
to nutrient exhaustion over time (Figures 1B and 1C). Glucose
levels were pronouncedly reduced in the culture medium of the600 Cell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc.cells incubated under these conditions (Figure 1B). Interestingly,
whereas the rate of increase in cell number of the control cells
started to decline at day 7 and was completely stalled at day
11, proliferation of PKCz-deficient cells was not impaired under
these conditions (Figure 1D). Cell-cycle analyses demonstrated
that, whereas shNT cells underwent massive apoptosis under
nutrient-scarce conditions, shPKCz cells did not (Figure S1A
available online). Consistently, cells with reduced levels of
PKCz had lower caspase-3 activity (Figure 1A, middle). No major
differences in cell-cycle progression were observed between
shNT and shPKCz cells (Figure S1A). shNT cells depleted
glucose from the culture medium more efficiently than shPKCz
cells, even at time points in which shPKCz cells outnumbered
shNT cells (Figures 1B and 1D). shPKCz cells depleted glutamine
from the medium more efficiently than shNT cells (Figure 1C).
This indicates that glucose is consumed more actively in shNT
than in shPKCz cells, as confirmed by the data of Figures 1E
and 1F showing that shNT cells displayed higher levels of
glucose consumption and lactate production than shPKCz cells.
PKCz-deficient tumor cells were resistant to apoptosis induced
by glucose deprivation (Figures S1B and 1G). These observa-
tions were also confirmed in other human cancer cells and with
three different shRNAs of PKCz (Figures S1C and S1D). We
have been able to maintain shPKCz but not shNT cells in culture
in the absence of glucose for prolonged times, with glucose-
free medium change every 2 days (Figure S1E). Reconstitution
of shPKCz cells with wild-type (WT) but not with kinase-
dead PKCz completely abolished the enhanced proliferation of
shPKCz cells (Figure 1H), demonstrating that PKCz-deficient
cells are able to activate an emergency mechanism in response
to nutrient stress caused by the lack of glucose. Consistently,
ATP levels are dramatically reduced in shNT cells in the absence
of glucose but are maintained at normal levels in viable shPKCz
(Figure S1F). SW620, a more aggressive variant of SW480, dis-
played little or no PKCz (Figure S1G). Interestingly, similarly to
SW480 shPKCz cells, SW620 cells were able to survive and
proliferate under nutrient stress conditions (Figure S1H). Consis-
tently, WT but not kinase-dead PKCz was able to repress the
ability of SW620 cells to resist nutrient stress (Figure 1I).
Role of PKCz in Stress Signaling in Response to Glucose
Deprivation
We performed experiments to establish the mechanisms where-
by PKCz deficiency allows cell proliferation under conditions of
nutrient deprivation. Nutrient exhaustion (Figure 2A) or incuba-
tion of cells under glucose-free conditions (Figure 2B) both led
to activation of PKCz and its nuclear translocation, whereas
the other aPKC, PKCl/i, was not affected (Figures 2C, S2A,
and S2B). Ser-311 phosphorylation of a bona fide substrate of
PKCz (RelA; Duran et al., 2003) in immunoprecipitates from the
same extracts of Figure 2A independently confirms that PKCz
is activated during nutrient exhaustion (Figure 2A, lowest two
panels). Consistent with the requirement for glucose to maintain
the energetic demands of cancer cells, AMPK was activated in
shNT cells incubated in glucose-free culture medium (Figures
2D and S2B). Intriguingly, reduction in PKCz levels led to lower
amounts of phospho-AMPK under these conditions (Figure 2D).
Phospho-ACC and phospho-ULK1 levels were in keeping with
elevated AMPK activity (Figure 2D). Autophagy was induced in
shNT cells in response to glucose deprivation, but this induction
was significantly inhibited in PKCz-deficient cells (Figure 2D).
Increased LC3-II levels can be a consequence of enhanced
autophagy or decreased autophagic flux. To determine which
of these two effects could account for the results in Figure 2D,we incubated shNT and shPKCz cells in the absence of glucose,
with or without a combination of two protease inhibitors (E64
and pepstatin) that interrupt autophagic flux as determined by
the accumulation of LC3-II (Figure 2E). These data demonstrate
that PKCz deficiency results in decreased AMPK activation and
autophagy when cancer cells are incubated in glucose-free
conditions. mTOR activity, which is normally shut down under
conditions of energy depletion, is likewise inhibited in glucose-
free medium in shNT but not in shPKCz cells (Figure 2D). These
results demonstrate a direct or indirect role for PKCz in the
biochemical response to nutrient stress activated by the lack
of glucose in cells that require this nutrient for survival and
growth.
AMPK and autophagy are two survival mechanisms set in
motion by cells under low energetic environments (Hardie,
2007; Kroemer et al., 2010). The activation of fatty acid oxidation
and autophagy, two processes under the control of AMPK, are
mechanisms that result in enhanced cell survival. Consistent
with the AMPK/ACC results (Figure 2D), PKCz deficiency
impaired the enhanced fatty acid oxidation triggered by glucose
deprivation (Figure 2F). Interestingly, in the absence of glucose,
shNT cells exhibited increased JNK activity and the expression
of its downstream target c-Jun (Figures 2G and S2B). In contrast,
the activation of this pathway was completely blunted in shPKCz
cells under identical culture conditions (Figure 2G). Similarly,
the activation of JNK, which was dramatically activated in
WM35 melanoma cells cultured in the absence of glucose, was
completely inhibited in PKCz-deficient WM35 cells (Figure S2C).
One interpretation of these results is that PKCz deficiency
prevents nutrient stress in cancer cells, which is translated into
a failure to activate the biochemical emergency signals that are
normally set in motion when cells sense a potential energetic
or metabolic catastrophe. Therefore, PKCz-deficient cells do
not shut down their anabolic activities, as manifested by a lack
of effect on mTORC1 activity, when incubated in glucose-free
conditions (Figure 2D), as well as by the ability of PKCz-deficient
cells to proliferate under nutrient stress (Figures 1D and S1E).
Role of Stress Signaling in Cell Proliferation in the
Absence of Glucose
One possibility is that all the biochemical stress-induced sig-
naling is the consequence, rather than the cause, of an enhanced
energetic and metabolic state of PKCz-deficient cells grow-
ing under glucose-deprived conditions. Therefore, inhibition of
these parameters in shNT cells should have no impact on the
failure to survive and proliferate in the absence of glucose. To
address the role of autophagy, we generated ATG5-deficient
cells (shATG5) and asked whether the inhibition of autophagy
in shNT cells was sufficient to promote cell growth in the
absence of glucose. ATG5 levels were reduced in SW480 cells
infected with shRNA for ATG5, and that autophagy was impaired
as detected by the accumulation of p62 (Figure S2D). Impaired
autophagy in shNT cells did not result in enhanced cell survival
and proliferation under glucose-free conditions (Figure S2E).
Similarly, activation of AMPK with AICAR in shPKCz cells, or
inhibition of AMPK with compound C in shNT cells, did not
affect the ability of shPKCz cells to grow nor did it change the
ability of shNT cells to be rescued from a lack of proliferation inCell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc. 601
Figure 2. PKCz Deletion Impairs Glucose Deprivation-Induced Stress Signaling
(A and B) Cell lysates from SW480 cells cultured under nutrient exhaustion (A) or under glucose-deprived (B) conditions were analyzed by immunoblotting with
phospho-PKCz-T410 (p-PKCz), PKCz, and actin antibodies. PKCz activity toward RelA was determined in the corresponding immunoprecipitates (A). Results are
representative of three experiments.
(C) Normal or glucose deprived for 24 hr, SW480 cells were coimmunostained for PKCz (left) or PKCl (right) and DAPI. Scale bar, 20 mM. Images are repre-
sentative of three experiments.
(D) Cell lysates from SW480 control (shNT) or PKCz-deficient (shPKCz) cells cultured under glucose-deprived conditions were analyzed by immunoblotting with
the specified antibodies. Results are representative of three experiments.
(E) SW480 shNT or shPKCz cells cultured under glucose-deprived conditions with or without E64d (10 mg/ml) and pepstatin A (10 mg/ml) treatment. LC3 and actin
protein levels were analyzed by western blot. Results are representative of three experiments.
(F) Fatty acid oxidation was measured in SW480 shNT or shPKCz cells cultured as above for 36 hr. Results are the mean ± SEM (n = 3). cpm, counts per minute.
(G) Cell lysates from SW480 shNT or shPKCz cells cultured as above were analyzed by immunoblotting for phospho-JNK, c-Jun, and actin. Results are
representative of three experiments.
See also Figure S2.glucose-free medium (Figure S2F). We next generated SW480
cells with normal (shNT) or depleted levels of AMPK (shAMPK)
in a shNT or shPKCz background and determined their ability
to proliferate in glucose-free medium. AMPK was knocked
down in both cell lines (Figure S2G). AMPK deficiency does not
affect the proliferative properties of shNT or shPKCz cells in
glucose-free conditions (Figure S2H). Also, SP600125-induced
inhibition of JNK did not allow shNT cells to grow in glucose-
free medium (Figure S2I). JNK knockdown had no effect on the
response of either cell line to glucose deprivation (Figures S2J
and S2K). These results indicate that the lack of stress signaling602 Cell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc.in glucose-deprived PKCz-deficient cells cannot explain their
higher proliferative response. One possibility is that PKCz-defi-
cient cells are able to reprogram their metabolism for the efficient
utilization of fuels other than glucose, allowing them to survive
and proliferate in the absence of that nutrient.
Cancer Metabolic Control by PKCz
Genome-wide transcriptome analysis demonstrated that PKCz-
deficient cells displayed gene alterations in pathways consistent
with the use of glutamine as a glucose alternative (p = 1.1 3
1039; FDR = 2.79 3 1036; Table S1). In fact, shPKCz cells
consumed glutamine more rapidly than did the shNT cells
(Figure 3A), suggesting that the ability to utilize glutamine as
the primary carbon source underlies the survival advantage
of shPKCz cells when glucose is limited. We next grew shNT
and shPKCz cells in media that contained glutamine as the
sole metabolic substrate. In separate experiments, the gluta-
mine present in the media was composed of either 15N at the
a-nitrogen, or 13C at all carbon positions. 15N incorporation
into both serine and glycine was significantly increased in the
shPKCz cells, indicating that the PHGDH/PSAT pathway was
more active in this cell line (Figures 3B and 3C). No difference
was found in aspartate or alanine biosynthesis under these
conditions (Figure S3A). When cells were labeled with 13C-gluta-
mine under the same conditions, the entire serine-glycine
biosynthetic pathway was specifically increased in the shPKCz
cells as evidenced by increased labeling of 3-phosphoglycerate
(3PG), serine, and glycine (Figure 3D, left, white and black
bars), whereas other glutamine-utilizing pathways remained
unchanged (Figures S3B–S3D). This suggests that the serine
biosynthetic pathway is a primary mechanism for glutamine utili-
zation in the shPKCz cells. Gene expression analysis of enzymes
in this pathway demonstrated that PKCz deficiency resulted in
increased expression of PSAT1 and PHGDH at the mRNA and
protein level (Figures 3E and 3F). The reconstitution of shPKCz
cells with WT but not with kinase-dead PKCz significantly
reduced the increase in PHGDH in shPKCz cells (Figure 3G).
PHGDHcatalyzes the conversation of 3PG to 3-phosphohydrox-
ypyruvate (3PHP) (Figure 3C). PSAT then converts 3PHP to
phosphoserine in a biochemical reaction that transfers the
a-nitrogen of glutamate to 3PHP while producing a-ketogluta-
rate (Figure 3C). This can be interpreted to mean that at least
one of the important tumor-suppressing functions of PKCz is
to prevent nutrient stress cells from redirecting their metabolism
to a more efficient utilization of glutamine. Phosphoserine phos-
phatase (PSPH), the enzyme that catalyzes the final step of
serine biosynthesis, was not significantly increased (Figure S3E),
suggesting that it is indeed the a-ketoglutarate-producing
portion of this pathway that is most critical for cell survival (Fig-
ure 3C). The expression of other aminotransferases was un-
changed (Figure S3E).
To test the relevance of this metabolic pathway, we simulta-
neously knocked down PKCz and PHGDH. PHGDH reduction
impaired serine and glycine production from 13C-glutamine
even in shPKCz cells, demonstrating the effective inactivation
of this metabolic cascade (Figure 3D). Furthermore, the knock-
down of PHGDH levels not only impairs serine and glycine
production but also the generation of 3PG (Figure 3D). This indi-
cates that the regulation of PHGDH by PKCz is essential to acti-
vate glutamine metabolism to produce 3PG and to activate the
serine/glycine pathway. Importantly, the loss of either PHGDH
or PSAT1 completely abolished the proliferation of PKCz-defi-
cient cells in the absence of glucose (Figures 3H and 3I). Further-
more, the simultaneous knockdown of PKCz and either PSAT1
or PHGDH restores the activation of AMPK and JNK in the
PKCz-deficient cells to levels comparable to those of shNT cells
when all are incubated in the absence of glucose (Figure 3J). This
supports the idea that PKCz is not a direct regulator of the
biochemical stress signals but rather regulates the metabolicstate of the cell, which in turn modulates the stress signal trans-
duction pathways.
Regulation of PHGDH by PKCz Phosphorylation
Based on these observations, we would predict that the overex-
pression of PHGDH in SW480 cells with normal levels of PKCz
should be sufficient to confer these cells resistance to nutrient
stress. However, the simple overexpression of PHGDH is not
sufficient to confer SW480 cells the ability to survive and prolif-
erate under nutrient-scarce conditions (Figure 4A). Metabolic
analysis demonstrates the lack of differences between SW480
cells that overexpress and those that do not overexpress
PHGDH (data not shown). One potential explanation to these
observations is that PKCz, in addition to lowering PHGDH levels,
would also directly repress PHGDH activity by direct phosphor-
ylation. Interestingly, our data demonstrate that PHGDH is a
bona fide direct substrate of PKCz (Figure 4B). To determine
the phosphorylated residues of PHGDH, titanium dioxide
(TiO2)-based phosphopeptide enrichment was performed on
tryptic digests of in vitro-phosphorylation reactions, followed
by HPLC-tandem mass spectrometry (MS/MS) analysis. MS/
MS spectra showed that PKCz phosphorylates PHGDH at resi-
dues Ser55, Thr57, and Thr78 (Figure 4C). These three residues
were not phosphorylated in PKCz- or PHGDH-only controls and
are highly conserved among species, and according to the
structure of PHGDH (Protein Data Bank ID code 2g76), might
play critical roles in its activity (Figures 4D and 4E). Thr78 lies
adjacent to both the substrate and cofactor binding sites, and
mutation of this residue would predictably directly decrease
binding efficiencies in both sites (Figure 4E). Thr57 does not
directly contact either ligand but plays an important role stabi-
lizing the loop harboring Ser55 as well as Arg54, which syner-
gizes with Arg135 directly adjacent to the expected position
of the substrate 3-phospho-D-glycerate. A previous study has
identified an Arg135 missense mutation in PHGDH deficiency
(Tabatabaie et al., 2009). Therefore, mutations of Thr57 will likely
cause a similar effect by destabilizing the loop where Arg54
resides and, thus, abrogating substrate binding. To test these
predictions, we independently mutated Ser55, Thr57, and
Thr78 and determined the impact that these mutations have on
the enzymatic activity in vitro. T/A and T/E mutations of
Thr57 severely abrogated PHGDH activity (Figure 4F). Although
identical mutations of Thr78 have a lower impact on PHGDH’s
Vmax, however, the T/E mutation severely affected the KM (Fig-
ure 4G). S/E mutation of Ser55 reproducibly inhibited PHGDH
activity to a greater extent than S/A mutation (Figure 4H). A
construct harboring a triple 55/57/78 E or A mutant completely
abrogated PHGDH activity (Figure 4I). Also, the in vitro phos-
phorylation of PHGDH by PKCz results in a significant inhibition
of PHGDH’s enzymatic activity (Figure 4J). Collectively, these
results demonstrate that PHGDH’s Ser55, Thr57, and Thr78
are functionally relevant targets of PKCz. We next treated shNT
and shPKCz cells under normal or glucose-deprivation condi-
tions, after which PHGDH was immunoprecipitated and ana-
lyzed by immunoblotting with an anti-phospho-Thr antibody.
Results of Figure 4K demonstrate that PHGDH is Thr phosphor-
ylated at 48 hr under glucose-deprived conditions in a PKCz-
dependent manner, consistent with the kinetic of PHGDHCell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc. 603
Figure 3. PKCz Controls Metabolism by Reprogramming Glutamine Utilization
(A) The net consumption of glutamine by SW480 control (shNT) or PKCz-deficient (shPKCz) cells was determined by enzymatic assays over 24 hr of growth.
Results are the mean ± SEM (n = 4).
(legend continued on next page)
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induction levels shown in Figure 3F. We did not observe
increased serine phosphorylation of PHGDH upon glucose
deprivation under similar conditions (data not shown). To further
determine whether the PKCz-targeted-identified residues are
actually phosphorylated in vivo, we generated SW480 cells ex-
pressing flag-tagged PHGDH in either WT or a triple S55/T57/
T78 mutant. Interestingly, although glucose deprivation resulted
in a robust Thr phosphorylation of WT PHGDH at 48 hr, as in the
previous experiment (compare Figures 4K and 4L), this phos-
phorylation was undetectable in the PHGDH triple mutant (Fig-
ure 4L). This phosphorylation event was not detected at earlier
time points, including 24 hr (Figure S4). These results demon-
strate that PGHDH is phosphorylated by PKCz at the identified
residues in vivo under conditions of nutrient stress. To confirm
the functional relevance of these phosphorylations, MDA-MB-
231 cells, which have low PKCz levels and undetectable levels
of PHGDH, were transfected with WT or triple-mutant PHGDH
and were incubated under conditions of serine deprivation, after
which their ability to survive and proliferate was determined
by trypan blue exclusion assay. Interestingly, WT PHGDH, but
not its triple mutant, conferred MDA-MB-231 cells the ability
to proliferate under these conditions (Figure 4M). Collectively,
these results indicate that PHGDH Thr57 and Thr78 are most
likely the inducible phosphorylation substrates of PKCz in cells
under nutrient stress and that they play critical roles in PHGDH
activity and functions accounting for the involvement of PKCz
as a metabolic tumor suppressor.
Tumor-Suppressive Role of PKCz in Intestinal Cancer
We next sought to determine whether the loss of PKCz in
intestinal tumors also results in increased levels of PHGDH,
PSAT1, or both, correlating with enhanced carcinogenesis and
reduced apoptosis. To generate the tumor samples needed to
address this question, we crossed PKCz knockout (KO) mice
with APCMin/+ mice (widely accepted model of intestinal tumori-
genesis). Kaplan-Meier survival plots for APCMin/+PKCz/ ver-
sus APCMin/+PKCz+/+ mice demonstrated that the lack of PKCz
promoted intestinal cancer. APCMin/+PKCz/ mice exhibited
a median survival of 26 weeks, whereas 100% of APCMin/+
PKCz+/+ mice were alive at 30 weeks, which was the extent of
the duration of the study (Figure 5A, open symbols). Another(B) The percentage of glycine and serine containing 15N from glutamine in shNT o
the a position. Results are the mean ± SEM (n = 2–3).
(C) Metabolic scheme depicting biosynthetic routes to serine and glycine from g
(D) The percentage of 3PG, serine, and glycine containing 13C from glutamine isot
growth, or in these same cells in which PSAT1 or PHGDH has been knocked down
SEM (n = 4). Knockdown efficiency was determined by immunoblotting in cell ly
(E) PHGDH and PSAT1 mRNA expression was determined by quantitative PCR
Results are the mean ± SEM (n = 3).
(F) PHGDH protein levels were determined by western blot in extracts of SW480 s
time. Results are representative of three experiments.
(G) PHGDH protein levels were determined by western blot in extracts of SW480
PKCz cultured as above. Results are representative of three experiments.
(H and I) Cell viability of SW480 cells with the indicated lentiviral knockdown cu
determined by trypan blue exclusion assay (H). Cell lysates were analyzed by imm
(J) Cell lysates from SW480 cells with the indicated lentiviral knockdown were c
lysates were analyzed by immunoblotting for the specified proteins. Results are
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S3 and Table S1.set of mutant mice was fed a Western diet (WD) to accelerate
the appearance of tumors (Baltgalvis et al., 2009). Under these
conditions, 100% of the APCMin/+PKCz/ KO mice had died
at 26 weeks of treatment, with a median survival of 22 weeks,
whereas 80% of the APCMin/+PKCz+/+ mice were still alive
at that time (Figure 5A, filled symbols). Therefore, APCMin/+
PKCz/ mice died significantly earlier than APCMin/+PKCz+/+
littermate controls, independent of the diet. There were also
significant differences in weight gain between APCMin/+PKCz+/+
and APCMin/+PKCz/mice after 4 weeks on theWD (Figure 5B).
The weight loss of the APCMin/+PKCz/ group after 8 weeks on
the WD, along with the appearance of other detrimental condi-
tions such as anemia, rectal prolapse, and limited survival,
dictated the completion of the study when the mice were 16–
18 weeks old. PKCz deficiency induced a higher total number
of polyps (Figures 5C and 5D), and these were larger (tumor
area) than those in PKCz+/+ mice (Figure 5E). APCMin/+PKCz/
tumors were also more aggressive than those in APCMin/+
PKCz+/+ mice, with adenomas with significant nuclear atypia
(including vesicular nuclei, prominent nuclei, and a loss of
nuclear polarity) and marked architectural distortion frequently
including a cribriform pattern of growth (adenomas with high-
grade dysplasia) (Figure 5F). Areas with more significant cribri-
forming and an expanding-type infiltration into the lamina propria
by back-to-back glands (intramucosal adenocarcinoma) were
also identified in the PKCz-deficient APCMin/+ tumors (Figure 5G).
The majority of these lesions displayed strong staining for
b-catenin (Figures 5H and 5I). In contrast, APCMin/+PKCz+/+
mice showed either single dysplastic crypts or several adjacent
dysplastic glands with moderate nuclear pleomorphism but
preservation of nuclear polarity and absence of a complex archi-
tecture (adenomas with low-grade dysplasia) (Figure 5F). Collec-
tively, these results indicate that the genetic inactivation of PKCz
leads to increased intestinal tumorigenesis by APC inactivation,
which is consistent with a role for PKCz as a tumor suppressor.
Analysis of Affymetrix mouse genome arrays (Gene Expression
Omnibus [GEO] data set DS389) (Paoni et al., 2003) demon-
strated significant PKCz downregulation in adenomas and ade-
nocarcinomas from APCMin/+ mice as compared with normal
tissue from the same mouse line and when APCMin/+ samples
were compared with WT control mice (Figure 5J).r shPKCz cells after 24 hr of growth. Glutamine was isotopically labeled only at
lucose and glutamine.
opically labeled at all five carbons in SW480 shNT or shPKCz cells after 24 hr of
. Glutamine was isotopically labeled at all five carbons. Results are the mean ±
sates (right).
in SW480 shNT or shPKCz cells cultured under glucose-deprived conditions.
hNT or shPKCz cells cultured under glucose-deprived conditions for indicated
shNT, shPKCz, or shPKCz cells reconstituted with either WT or kinase-dead
ltured under glucose-deprived conditions for 72 hr. Number of the cells was
unoblotting for the specified proteins (I). Results are the mean ± SEM (n = 3).
ultured under normal or glucose-deprived conditions for 72 hr after which cell
representative of three experiments.
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Figure 4. PKCz Phosphorylation Regulates PHGDH Activity
(A) Cell viability of SW480 cells stably expressing PHGDH cultured under glucose-deprived conditions. Results are the mean ± SEM (n = 3). Expression of Flag-
tagged PHGDH was confirmed by immunoblotting with Flag antibody (inset).
(B) PKCz phosphorylates PHGDH in vitro.
(C) MS/MS spectra of phosphopeptides containing the phosphoserine (pS) 55 (I), phosphothreonine (pT) 57 (II), or the pT78 (III) site of PHDGH. Fragment ions are
shown, as is the sequence coverage due to identified fragment ions. All of the highest peaks were explained, but for clarity, they are not all annotated. m/z, mass-
to-charge ratio.
(D) Ser55, Thr57, and Thr78 phosphorylation sites are highly conserved among human, rat, monkey, andmouse. Identified phosphopeptides are shown above the
sequence alignments.
(E) Ser55, Thr57, and Thr78 in the crystal structure of human PHGDH. Overall view of the PHGDH dimer (Protein Data Bank ID code 2g76) with the two chains of
the dimer colored in green and cyan, respectively. The relative positions of NAD (black circle) and substrate analog D-malate (blue circle), as well as Ser55, Thr57,
(legend continued on next page)
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PKCz Loss Reduced Apoptosis in the Cancerous
Intestine of APCMin/+ Mice and Humans
No changes in Ki67 staining were observed in APCMin/+PKCz/
tumors as compared with APCMin/+PKCz+/+ controls (Figures 6A
and 6B). In contrast, PKCz deficiency led to a reduction in the
number of activated caspase-3-positive cells in APCMin/+ tumors
(Figures 6C and 6D). To test the physiological relevance of the
increased expression of PHGDH and PSAT1 induced by PKCz
deficiency in cultured SW480 cells, we analyzed these two
mRNAs in tumor samples from APCMin/+ mice with or without
PKCz deficiency. Importantly, PHGDH and PSAT1 were signifi-
cantly increased in PKCz-deficient tumors as compared with
WT (Figure 6E). To further link themetabolic effects of PKCz defi-
ciency in cell culture experiments to the in vivo phenotype of
PKCz-deficient APCMin/+ mice, tumor explants from these mice
and their corresponding APCMin/+WT littermates were incubated
with 15N-labeled glutamine for 24 hr, after which the labeling into
serine and glycine was determined as above. Interestingly, 15N-
glutamine-derived labeling into serine and glycine was signifi-
cantly increased in the PKCz-deficient tumors as compared
with their counterpart WT controls (Figure 6F).
We next subcutaneously implanted shNT or shPKCz cells in
nudemice. Interestingly, the growth rate of PKCz-deficient xeno-
grafts (shPKCz) was higher in comparison with those derived
from control cells (shNT). PKCz-deficient xenograft volume
was significantly increased by day 39 and continued to increase
until day 46 (Figure 6G). Cells with double PHGDH and PKCz
knockdown were unable to form xenograft tumors, consistent
with the notion that PHGDH is critical for tumor progression
(data not shown). These results demonstrate that PKCz is a tumor
suppressor likely by controlling the ability of cancer cells to
respond to nutrient stress by acting upstream of PHGDH. In
keeping with this, gene expression analysis of publicly available
microarray data demonstrated that PKCz is downregulated in
human colorectal cancers as compared with normal colon tissue
(GEO data set GSE5206) (Kaiser et al., 2007) and underex-
pressed in cancers progressing to metastasis (Figure 7A) (GEO
data set GSE6988) (Ki et al., 2007). In addition, we analyzed
a human colorectal cancer data set (GEO data set GSE14333)
(Jorissen et al., 2009) that included expression data from 290
primary colorectal cancers of different Dukes stages. When
patients with stages B and C were stratified in low and high
PKCz groups, it became clear that those with low PKCz levels
showed a statistically significant decrease in disease-free sur-
vival (Figure 7B). Analysis of PKCz expression in a tissue micro-
array (TMA) consisting of 66 samples of colon cancer tissuesand Thr78 (red and yellow spheres) are indicated (left). Close-up view of the subst
and Arg54 and Arg135, which participate in binding of the substrate analog, are
(F–I) PHGDH enzymatic activities of T/A and T/Emutations of Thr57 (F) and Th
Thr78 sites/ AAA and Ser55/Thr57/Thr78 sites/ EEE mutations (I). Results ar
(J) PHGDH activity after in vitro phosphorylation by recombinant PKCz.
(K) Lysates and immunoprecipitates (IP) from SW480 shNT and shPKCz cells cul
immunoblotting to determine the level of phosphorylated Thr. Results are repres
(L) Lysates and immunoprecipitates from SW480 cells stably expressing Flag-PH
conditions for 48 hr were analyzed by immunoblotting to determine the level of p
(M) Cell viability of MDA-MB-231 cells stably expressing PHGDHWT, PHGDH AA
Number of cells was determined by trypan blue exclusion assay. Results are me
See also Figure S4.yielded similar results. Importantly, 42% (28 of 66) of the colon
adenocarcinomas analyzed were negative for PKCz expression
in the nucleus (Figures 7C and 7D). Samples with decreased
nuclear PKCz staining also showed diminished staining for acti-
vated caspase-3, as compared with tissues that stained posi-
tively for PKCz (Figures 7C and 7D). Therefore, human tumor
tissues show a positive correlation between PKCz levels and
caspase-3 activation. This is consistent with data from the
APCMin/+ mouse model, which showed lower activated cas-
pase-3 activity in PKCz-deficient tumors (Figures 6C and 6D),
and from SW480 cells with reduced levels of PKCz, which had
lower caspase-3 activity than control cells (Figures 1A and 1G).
When the same TMA was analyzed for PHGDH expression, we
found a significant negative correlation between nuclear PKCz
and PHGDH levels (Figures 7C and 7E), demonstrating that
the link between PKCz and this critical metabolic enzyme is
also apparent in human patients with cancer. Consistent with
PKCz playing a negative role in this serine-glycine pathway,
Figure 7F demonstrates a statistically significant inverse correla-
tion between the expression levels of PKCz and PSAT1 in human
patients with colorectal cancer (GEO data set GSE20916)
(Skrzypczak et al., 2010). Collectively, these results demonstrate
that PKCz is a tumor suppressor in intestinal cancer, in bothmice
and humans.
DISCUSSION
Understanding the differences between normal and tumor cells
with regard to metabolic homeostasis could provide an opportu-
nity for selective therapies in cancer. Considerable attention has
been paid to the metabolism of glucose in the tumor cell, which
has some characteristic features that could be exploited thera-
peutically. However, the metabolism of cancer cells is much
more complex, and recent studies have implicated the direct
action of oncogenes and tumor suppressors as potential modula-
torsof this function. In this regard,a keycharacteristic of the tumor
cell is plasticity manifested by a capacity to adapt to the harsh
conditions in which the tumor must expand, thus continuing to
satisfy the high demand for energy and anabolic building blocks
necessary for characteristic uncontrolled growth and survival.
This is of particular interest because some clinical data show
that tumors may be able to survive therapy by reprogramming
theirmetabolicneeds (Maetal., 2009). This, and the resultsshown
here, has important implications for the metabolic cancer thera-
peutics aimed at curtailing the supply or utilization of glucose.
Such treatments could trigger reprogramming of the metabolicrate binding site (right). The loop affected by mutation of Thr57 is colored gray,
indicated in stick representation (right).
r78 (G) sites, and S/A and S/Emutations of Ser55 site (H), and Ser55/Thr57/
e representative of three experiments.
tured under normal or glucose-deprived conditions for 48 hr were analyzed by
entative of three experiments. n.s., nonspecific.
GDH or Flag-PHGDH AAA mutant cultured under normal or glucose-deprived
hosphorylated Thr. Results are representative of three experiments.
A mutant, or EEE mutant cultured under serine-deprived conditions for 5 days.
an ± SEM (n = 3). ***p < 0.001.
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Figure 5. PKCz Deletion Enhances Intestinal Tumorigenesis in APCMin/+ Mice
(A) Kaplan-Meier survival graph for PKCz+/+/APCMin/+ (squares) and PKCz//APCMin/+ (circles) fed with a regular diet (RD; open symbols) or the WD (closed
symbols).
(B) Graph showing changes in total body weight after animals were fed with the WD for the indicated times. White bars represent PKCz+/+, gray bars indicate
PKCz/, black bars show PKCz+/+/APCMin/+, and striped bars demonstrate PKCz//APCMin/+. Values represent mean ± SEM of 14 mice per group.
(C) Number of polyps in distal small intestine sections of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ mice fed with the WD for 2 months. Values represent
mean ± SEM of at least 14 mice per group.
(D) Representative intestines from APCMin/+ mice with different genotypes. Each segment is equivalent to 1 cm.
(E) Graph showing the area of polyps in distal small intestine sections of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ mice fedwith theWD for 2months. Values
are mean ± SEM of at least 14 mice per group.
(F) Upper: a lower magnification of H&E of distal small intestine sections of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ mice. Tumors are delineated by
a dashed line. Lower: a higher magnification of low-grade adenoma (left) and high-grade adenoma (right). Scale bars, 50 mm.
(G) H&E of distal small intestine section of PKCz//APCMin/+ mice showing intramucosal adenocarcinoma. Lower: shows a higher magnification. Scale
bars, 50 mm.
(H) Immunodetection of b-catenin in tumors located in distal small intestine of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ mice. b-Catenin staining was
stronger in cytoplasm and nuclei of PKCz/ mice. Scale bars, 50 mm.
(I) Graph showing the number of samples staining positive for nuclear b-catenin in tumors located in distal small intestine sections of PKCz+/+/APCMin/+ (WT) and
PKCz//APCMin/+. Values represent mean ± SEM of at least ten mice per group.
(J) PKCz mRNA expression levels are significantly decreased in adenomas and carcinomas from APCMin/+ mice, as compared to normal tissue. t test, p = 0.01
(WT, n = 6; APCMin/+, n = 10).
*p < 0.05 and **p < 0.01.homeostasis of cancer cells, allowing for the efficient utilization
of alternative nutrients and metabolic pathways for growth, thus
increasing tumor aggressiveness. In this regard, our data demon-608 Cell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc.strate that PKCz is a determinant of metabolic plasticity and
suggest that attacking theWarburgeffectwould actually beeffec-
tive in cancer therapy as long as PKCz is activated.
A B C D
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Figure 6. PKCz Deletion Reduces Apoptosis in APCMin/+ Tumors
(A) Immunostaining for Ki67 in tumors located in distal small intestine sections of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ (KO) mice. Scale bar,
50 mm.
(B) Number of cells staining positive for Ki67 in tumor tissue. Values represent mean ± SEM of at least ten samples per group.
(C) Immunostaining for caspase-3 in tumors located in distal small intestine sections of PKCz+/+/APCMin/+ and PKCz//APCMin/+ mice. Scale bars, 50 mm.
(D) Number of cells staining positive for caspase-3 in tumor tissue. Values represent mean ± SEM of at least 14 samples per group.
(E) Quantitative PCR assays of PSAT1 and PHGDH were measured in distal small intestine sections of PKCz+/+/APCMin/+ (WT) and PKCz//APCMin/+ mice.
Results are the mean ± SEM (n = 3).
(F) The fraction of glycine and serine containing 15N from glutamine following 24 hr of incubation in tumor explants from PKCz+/+/APCMin/+ (WT) and PKCz//
APCMin/+ mice. Glutamine was isotopically labeled only at the a position. Results are the mean ± SEM (n = 5–6).
(G) SW480 shNT or shPKCz cell suspensions (5 3 106) were intradermally injected into each flank of nude mice. Tumors were allowed to develop for 46 days.
Tumor size was determined by direct measurement with a caliper and calculated by the formula: (widest diameter 3 smallest diameter2)/2. Results are mean ±
SEM (n = 5).
*p < 0.05 and **p < 0.01.Our findings demonstrate that PKCz deficiency allows glu-
cose-addicted human cancer cells to reprogram their metabo-
lism in response to glucose deprivation by increasing the
utilization of glutamine through a pathway that involves the
generation of 3PG, which is channeled through the serine
synthetic cascade due to the regulation of PHGDH and PSAT1,
two critical components of this metabolic pathway. Recent
studies support the relevance of the serine biosynthetic pathway
in cancer. Locasale et al. found that certain cancer cells divert
a large amount of glycolytic carbon to the serine biosynthetic
pathway, as indicated by amplification of the metabolic enzyme
PHGDH (Locasale et al., 2011). They showed that cell prolifera-
tion was severely attenuated by downregulation of PHGDH in
cells with an amplified PHGDH gene (Locasale et al., 2011).
Conversely, overexpression of PHGDH in normal mammary
epithelial cells resulted in phenotypic alterations, which sug-
gested that, although not transformed, these cells would be
prone to becoming malignant (Locasale et al., 2011). The chan-
neling of glycolytic products to this pathwaymight have anumberof metabolic advantages that could explain why the overexpres-
sion of PHGDH triggered certain protumorigenic functions and
its depletion impaired tumor cell proliferation in cancer cells
with high PHGDH copy number. Interestingly, another recent
study by Possemato et al. (2011) also established the 3PG/
serine pathway as relevant in cancer but showed that the
production of serine from glycolytic intermediates through this
mechanism was not likely to account for the metabolic advan-
tage of PHGDH-overexpressing cells. They proposed that the
utilization of glutamine to produce a-ketoglutarate coupled to
the conversion of phospho-hydroxypyruvate to phosphoserine
by PSAT1 was the relevant step for tumorigenesis (Possemato
et al., 2011).
In summary, our data show that in addition to glucose
utilization, the reprogramming of cellular metabolism to pro-
duce serine from glutamine underscores the importance of
serine biosynthesis for tumor cell survival and establishes
PKCz as a critical player in this important metabolic pathway
for cancer.Cell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc. 609
Figure 7. Tumor Suppressor Role of PKCz
in Human Colon Cancer
(A) Gene expression analysis of PKCz in human
colon cancer samples in public microarray data.
(B) Kaplan-Meier curves comparing the survival of
patients with high versus low expression of PKCz.
(C) Representative sections of PKCz, caspase-3,
and PHGDH immunostaining. Scale bars, 50 mm.
(D) Associated correlation of caspase-3 and PKCz
expression in human colon cancer TMA. Nuclear
PKCz expression positively correlates with active
caspase-3 levels. **p < 0.01.
(E) Associated correlation of PHGDH and PKCz
expression in human colon cancer TMA. Nuclear
PKCz expression negatively correlates with
PHGDH levels. *p < 0.05.
(F) Negative correlation between PKCz and PSAT1
mRNA levels in human colorectal carcinomas.EXPERIMENTAL PROCEDURES
Mice
The PKCz/ and APCMin/+ mice were described previously (Leitges et al.,
2001; Moser et al., 1990). All mice were born and maintained under
pathogen-free conditions. Animal handling and experimental procedures
conformed to institutional guidelines (Institutional Animal Care and Use
Committee). All genotyping was done by PCR. The WD (D12079B;
OpenSource Diets) was available ad libitum. Mice were sacrificed, and
sections of the small intestines, distal to the stomach and proximal to the
cecum, were carefully dissected. Mesentery tissue was removed, and the
intestine sections were flushed with PBS, fixed in 10% buffered formalin
for 24 hr and transferred to 70% ethanol for processing and sectioning.
Histological examination was performed on hematoxylin and eosin (H&E)-
stained sections.610 Cell 152, 599–611, January 31, 2013 ª2013 Elsevier Inc.Cell Culture
SW480, SW620, MW35, and MDA-MB-231 cells
were from ATCC. Cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 1%
glutamine, and 1% penicillin-streptomycin, in an
atmosphere of 95% air and 5% CO2. Lentiviruses
for the different target genes were made as
follows: shRNA-encoding plasmids were cotrans-
fected with psPAX2 and pMD2.G packaging plas-
mids into actively growing HEK293T cells by using
FuGENE 6 transfection reagent. Virus-containing
supernatants were collected 48 hr after transfec-
tion and filtered to remove cells, and target cells
were infected in the presence of 8 mg/ml poly-
brene. Cells were selected with puromycin after
infection. Retroviruses for the different target
genes were made as follows: pWZL-encoding
and pBabe-encoding plasmids were transfected
into actively growing Phoenix cells by using
FuGENE 6 transfection reagent. Virus-containing
supernatants were collected and treated as
above, and target cells were infected in the pres-
ence of 8 mg/ml polybrene. Cells were selected
with hygromycin or puromycin.
Viability Assay and Cell-Cycle Analysis
Cells were seeded onto 6-well plates in 10%
FBS-DMEM, washed with PBS twice after attach-
ment, and changed to the indicated medium. Cellviability was determined by trypan blue exclusion assay at the indicated time.
For cell-cycle analysis, cells were seeded as above and fixed in ethanol and
analyzed by propidium iodide (PI) staining (50 mg/ml in PBS) and flow cytom-
etry (FACScan; Becton Dickinson).
Statistical Analysis
Significant differences between groups were determined using the Student’s
t test. The differences between intensity of immunostaining in human TMAs
were evaluated using Fisher’s exact test as implemented in the SAS statistical
software. The significance level for statistical testing was set at p < 0.05.
ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE42186.
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